Wapner on Avastin

Always interesting and engaging, Jessica Wapner has discussed the bevacizumab (Avastin) saga and a recent recommendation made to the FDA that the drug is not appropriate for the treatment of breast cancer. It is a difficult example because the drug is prohibitively expensive, will evoke a positive response in a relatively small proportion of patients, … Continue reading Wapner on Avastin

Another approved drug may leave the market

Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to have marginal positive effects on the progression of cancer for some patients. It is a very difficult question to weigh … Continue reading Another approved drug may leave the market